$3.64
0.25.81%
At Close: -
$3.64
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
ADC Therapeutics
ADCTNYSE
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
ADC Therapeutics (NYSE:ADCT) Stock, Analyst Ratings, Price Targets, Forecasts
ADC Therapeutics SA has a consensus price target of $18.75 based on the ratings of 12 analysts. The high is $47 issued by Morgan Stanley on September 7, 2021. The low is $2 issued by Morgan Stanley on July 11, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Guggenheim on May 7, 2024, April 15, 2024, and March 28, 2024, respectively. With an average price target of $9.33 between HC Wainwright & Co., HC Wainwright & Co., and Guggenheim, there's an implied 156.41% upside for ADC Therapeutics SA from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
RBC Capital
Morgan Stanley
B of A Securities
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for ADC Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/30/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt | — | Initiates | → Overweight | Get Alert |
| 05/07/2024 | Buy Now | 119.78% | HC Wainwright & Co. | Robert Burns | $9 → $8 | Maintains | Buy | Get Alert |
| 04/15/2024 | Buy Now | 147.25% | HC Wainwright & Co. | Robert Burns | → $9 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | Buy Now | — | Guggenheim | Michael Schmidt | — | Reiterates | → Buy | Get Alert |
| 03/28/2024 | Buy Now | 202.2% | Guggenheim | Michael Schmidt | → $11 | Initiates | → Buy | Get Alert |
| 03/14/2024 | Buy Now | 119.78% | RBC Capital | Gregory Renza | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 03/06/2024 | Buy Now | 147.25% | HC Wainwright & Co. | Robert Burns | → $9 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2024 | Buy Now | 119.78% | RBC Capital | Gregory Renza | $6 → $8 | Maintains | Outperform | Get Alert |
| 02/20/2024 | Buy Now | 147.25% | HC Wainwright & Co. | Robert Burns | $3 → $9 | Maintains | Buy | Get Alert |
| 11/20/2023 | Buy Now | -17.58% | HC Wainwright & Co. | Robert Burns | $12 → $3 | Maintains | Buy | Get Alert |
| 11/09/2023 | Buy Now | — | TD Cowen | Boris Peaker | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/08/2023 | Buy Now | 64.84% | RBC Capital | Gregory Renza | $7 → $6 | Maintains | Outperform | Get Alert |
| 09/19/2023 | Buy Now | 229.67% | HC Wainwright & Co. | Robert Burns | → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | 119.78% | RBC Capital | Gregory Renza | $9 → $8 | Maintains | Outperform | Get Alert |
| 08/10/2023 | Buy Now | — | JP Morgan | Brian Cheng | — | Upgrade | Underweight → Neutral | Get Alert |
| 08/09/2023 | Buy Now | 147.25% | RBC Capital | Gregory Renza | $10 → $9 | Maintains | Outperform | Get Alert |
| 07/25/2023 | Buy Now | 229.67% | HC Wainwright & Co. | Robert Burns | → $12 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | -45.05% | Morgan Stanley | Jeffrey Hung | $5 → $5 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/20/2023 | Buy Now | 229.67% | HC Wainwright & Co. | Robert Burns | $20 → $12 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 174.73% | RBC Capital | Gregory Renza | $12 → $10 | Maintains | Outperform | Get Alert |
| 04/24/2023 | Buy Now | -45.05% | B of A Securities | Tazeen Ahmad | $7 → $2 | Downgrade | Neutral → Underperform | Get Alert |
| 02/13/2023 | Buy Now | 229.67% | RBC Capital | Gregory Renza | $18 → $12 | Maintains | Outperform | Get Alert |
| 01/24/2023 | Buy Now | 37.36% | Morgan Stanley | Matthew Harrison | $7 → $5 | Maintains | Equal-Weight | Get Alert |
| 01/04/2023 | Buy Now | 449.45% | HC Wainwright & Co. | Robert Burns | $21 → $20 | Maintains | Buy | Get Alert |
| 11/14/2022 | Buy Now | 92.31% | Morgan Stanley | Matthew Harrison | $11 → $7 | Maintains | Equal-Weight | Get Alert |
| 11/09/2022 | Buy Now | 449.45% | RBC Capital | Gregory Renza | $25 → $20 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | 92.31% | B of A Securities | Tazeen Ahmad | $14 → $7 | Downgrade | Buy → Neutral | Get Alert |
| 09/21/2022 | Buy Now | 37.36% | JP Morgan | Brian Cheng | → $5 | Initiates | → Overweight | Get Alert |
| 09/19/2022 | Buy Now | 476.92% | HC Wainwright & Co. | Robert Burns | $20 → $21 | Maintains | Buy | Get Alert |
| 09/09/2022 | Buy Now | 202.2% | Morgan Stanley | Matthew Harrison | $17 → $11 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/22/2022 | Buy Now | 449.45% | HC Wainwright & Co. | Robert Burns | $44 → $20 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | 696.7% | RBC Capital | Gregory Renza | $30 → $29 | Maintains | Outperform | Get Alert |
| 07/11/2022 | Buy Now | 1108.79% | HC Wainwright & Co. | Robert Burns | $54 → $44 | Maintains | Buy | Get Alert |
| 05/10/2022 | Buy Now | 367.03% | Morgan Stanley | Matthew Harrison | $30 → $17 | Maintains | Overweight | Get Alert |
| 05/10/2022 | Buy Now | 724.18% | RBC Capital | Gregory Renza | $34 → $30 | Maintains | Outperform | Get Alert |
| 04/12/2022 | Buy Now | 724.18% | Morgan Stanley | Matthew Harrison | $29 → $30 | Maintains | Overweight | Get Alert |
| 03/04/2022 | Buy Now | 1383.52% | HC Wainwright & Co. | Robert Burns | $55 → $54 | Maintains | Buy | Get Alert |
| 02/01/2022 | Buy Now | 696.7% | Morgan Stanley | Matthew Harrison | $47 → $29 | Maintains | Overweight | Get Alert |
| 11/09/2021 | Buy Now | 1108.79% | Wolfe Research | — | — | Initiates | → Outperform | Get Alert |
| 11/03/2021 | Buy Now | 834.07% | RBC Capital | Kennen MacKay | — | Maintains | Outperform | Get Alert |
| 09/07/2021 | Buy Now | 1191.21% | Morgan Stanley | — | — | Maintains | Overweight | Get Alert |
| 08/09/2021 | Buy Now | 806.59% | RBC Capital | Kennen MacKay | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for ADC Therapeutics (ADCT) stock?
The latest price target for ADC Therapeutics (NYSE:ADCT) was reported by Cantor Fitzgerald on May 30, 2024. The analyst firm set a price target for $0.00 expecting ADCT to fall to within 12 months (a possible -100.00% downside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ADC Therapeutics (ADCT)?
The latest analyst rating for ADC Therapeutics (NYSE:ADCT) was provided by Cantor Fitzgerald, and ADC Therapeutics initiated their overweight rating.
When was the last upgrade for ADC Therapeutics (ADCT)?
The last upgrade for ADC Therapeutics SA happened on August 10, 2023 when JP Morgan raised their price target to N/A. JP Morgan previously had an underweight for ADC Therapeutics SA.
When was the last downgrade for ADC Therapeutics (ADCT)?
The last downgrade for ADC Therapeutics SA happened on November 9, 2023 when TD Cowen changed their price target from N/A to N/A for ADC Therapeutics SA.
When is the next analyst rating going to be posted or updated for ADC Therapeutics (ADCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on May 30, 2024 so you should expect the next rating to be made available sometime around May 30, 2025.
Is the Analyst Rating ADC Therapeutics (ADCT) correct?
While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a initiated with a price target of $0.00 to $0.00. The current price ADC Therapeutics (ADCT) is trading at is $3.64, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.